OrbiMed-Backed Pinnacle Raises $89M Series B to Advance Oral Peptide Pipeline
Pinnacle has closed an $89M Series B round backed by OrbiMed to fund development of its oral peptide drug candidates, a growing area of biotech investment.
Pinnacle, a biotech company backed by healthcare-focused investment firm OrbiMed, has closed an $89 million Series B financing round. The capital is earmarked to advance the company’s pipeline of oral peptide therapeutics, according to reporting from Fierce Biotech. The raise signals continued investor confidence in the oral peptide space at a time when the category is drawing serious attention across the industry.
Details
Oral peptide drug development has long been considered one of the harder problems in pharmaceuticals. Peptides are typically fragile molecules that break down in the digestive system before they can reach the bloodstream in meaningful amounts. Companies working in this area are trying to solve that delivery challenge through a variety of formulation and chemistry strategies.
Pinnacle is one of several biotechs pursuing that goal. With OrbiMed as a key backer, the company now has a significant pool of capital to push its candidates further through development. The $89 million Series B adds to whatever funding the company had previously raised, though the full details of Pinnacle’s earlier rounds and the specific candidates in its pipeline were not disclosed in the Fierce Biotech report.
OrbiMed is one of the largest dedicated healthcare investment firms in the world, with a track record of backing companies across biotech, pharma, and medical devices. Its involvement in a Series B of this size suggests meaningful conviction in Pinnacle’s approach and team.
The broader race to develop effective oral peptides has picked up pace in recent years. Oral GLP-1 receptor agonists, in particular, have attracted billions in investment from both large pharmaceutical companies and smaller biotechs. Whether Pinnacle’s pipeline overlaps with that category or focuses on other therapeutic targets is not yet clear from what’s been reported.
Why It Matters
For anyone following the peptide space, this funding round is worth noting for a few reasons.
First, the dollar amount is substantial. An $89 million Series B is a serious commitment, and it suggests the investors involved believe oral peptide delivery is a solvable problem with real commercial potential. That kind of capital doesn’t flow toward science that investors think is a dead end.
Second, it keeps pressure on the delivery question that has defined this corner of biotech for years. Injectable peptides are well-established, and they work. But a meaningful portion of patients and clinicians would prefer an oral option if the efficacy holds up. Each round of funding directed at oral formulations is another bet that the field is getting closer to making that a reality.
Third, it’s a signal about where smart healthcare money is going right now. OrbiMed backing a company specifically focused on oral peptide pipelines, at this stage and at this size, tells you something about sentiment in the market heading into the second quarter of 2026.
What’s still unclear is the specific indication or indications Pinnacle is targeting, the stage of its lead candidates, or what timeline the company is working toward for clinical data readouts. Those details, if and when they’re released, will matter a lot for understanding whether this round translates into meaningful near-term progress.
What’s Next
Pinnacle will likely use the Series B proceeds to run or expand clinical trials, build out its team, and potentially advance additional pipeline candidates from research into development. The company may also use the capital to continue refining its core oral delivery technology, whatever form that takes.
Investors and observers in the peptide space will be watching for any clinical updates Pinnacle puts out over the coming months. Data on how well its oral candidates perform in humans will be the real measure of whether the company’s approach is working. Until then, the raise itself is the news.
OrbiMed will presumably be active in helping shape Pinnacle’s strategy as the company moves into its next phase of growth.
Related Reading
Original Source
Fierce Biotech →